ARGENTA
Argenta, the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health, announced today that it has acquired Klifovet, the leading CRO and Regulatory Affairs consultancy organization in Europe. Financial details of the transaction were not disclosed. Klifovet founder and CEO Dr. Klaus Hellmann will continue to lead Klifovet and will join Argenta’s senior leadership team.
Founded in 1997 by Dr. Klaus Hellmann and located in Munich, Germany, Klifovet has built a leading reputation in the animal health industry, providing extensive expertise in clinical research and regulatory affairs. Its ~50 employees have had successful involvement in hundreds of studies, and their expertise and knowledge has been critical to numerous marketing authorizations for pharmaceutical, biological, immunological, and novel therapies. Its client base comprises the world’s top animal health and nutrition companies as well as many promising startups.
“The acquisition of Klifovet, and the expansion into the EU, is part of Argenta’s growth strategy and provides our customers the opportunity for a seamless, global Molecule to Market product development experience,” said Ben Russell, CEO of Argenta. “Importantly, Argenta and Klifovet share strategic and cultural values built around customer excellence, teamwork, partnership, and innovation. I am very pleased to welcome Klifovet as a valued member of the Argenta Group and collectively work to continue to advance animal health to the benefit of our clients.”
The combined business will be a global, full-value strategic partner, stimulating innovation and supporting large and small animal health and nutrition companies. Klifovet will particularly complement Argenta's Clinical & Regulatory Services team based in the United States, offering an unparalleled level of expertise, and access to the largest transatlantic CRO capability in animal health.
“Joining forces with the Argenta Group is 100% in line with Klifovet’s vision of becoming the leading international full-service provider for the development and maintenance of products for animal health, nutrition and wellbeing. The two leading CROs, with a presence in the EU and US, combined with the know-how and capabilities in manufacturing, regulatory services, project management, and product development, create the world’s leading animal health CDMO and CRO. It provides unique and excellent opportunities for both our clients and employees. I am truly convinced this to be a perfect fit and look forward to a great future within the Argenta Group,” said Klaus Hellmann, CEO of Klifovet.
Argenta was advised on the transaction by Stonehaven Consulting AG, a global consulting firm focused on animal health.
About Argenta
Founded in 2006 in New Zealand, Argenta’s talented, diverse and committed employees work on a daily basis to deliver excellence in animal health to customers around the world. With research and GMP manufacturing operations in New Zealand, the United States and the United Kingdom, Argenta holds a unique position as the only combined global contract research organization (CRO) and contract development & manufacturing organization (CDMO) dedicated to animal health. Argenta operates from “Molecule to Market” in partnership with customers of all sizes from all corners of the world, supporting their Research & Development, clinical research, regulatory, scale up and manufacturing needs along their veterinary product development journey. For more information about Argenta, please visit www.argentaglobal.com
About Klifovet
Klifovet AG, based in Munich, Germany, was founded in 1997 and is a full-service Contract Research and Development Organization (CRO), offering regulatory affairs, pre-clinical and clinical studies, GMP compliant manufacturing including clinical supplies, quality assurance, data management and statistical analyses for the animal health and nutrition industry. Where relevant, the organization assures that services comply with VICH GCP, GLP, GCP, GMP, GPhVP and ISO 9001 requirements. Klifovet supports its clients in all aspects of the development and maintenance of products for the animal health and nutrition market. For more information about Klifovet, please visit www.klifovet.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005309/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release
Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at
ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline17.11.2025 07:00:00 CET | Press release
At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters™*1-3 Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 The company also presented new phase III data on its investigational product Relfydess™ (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Inje
UBS and Ant International Partner on Blockchain-Based Real-Time Cross-Border Payments Settlement and Liquidity Management17.11.2025 05:42:00 CET | Press release
UBS has entered a strategic partnership with Ant International, a leading global digital payment, digitisation, and financial technology provider, to explore innovations in blockchain-based tokenised deposits to support Ant International’s global payments settlement and liquidity management. Both parties signed a Memorandum of Understanding (MoU) at UBS’s flagship office at 9 Penang Road in Singapore. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116743090/en/ From left to right: Young Jin Yee, Co-Head UBS Global Wealth Management Asia Pacific and Country Head Singapore, Kay Tin Khoo, Head Corporate Institutional Clients Asia Pacific, UBS, Kelvin Li, General Manager of Platform Tech at Ant International, and Douglas Feagin, President of Ant International at the MoU signing ceremony at UBS Singapore office at 9 Penang Road. Under the MoU, Ant International will leverage UBS Digital Cash, a blockchain-based payment platfor
Nitto Extends Partnership with the ATP Until 203017.11.2025 04:24:00 CET | Press release
Nitto Denko Corporation (Headquarters: Osaka, Japan; President: Hideo Takasaki; hereafter “Nitto”)(TOKYO:6988) is pleased to announce the extension of its partnership with the ATP for an additional five years, through 2030. Under this renewed agreement, Nitto will continue its role as the Title Partner of the Nitto ATP Finals, the season-ending championship, in collaboration with the ATP and the Italian Tennis and Padel Federation (FITP). By sponsoring this tournament, recognized as one of the most sustainable events on the ATP Tour, Nitto aims to inspire and amaze while pursuing further growth as a global company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116197903/en/ Nitto Extends Partnership with the ATP Until 2030 : ©Corinne Dubreuil/ATP Tour Since 2017, Nitto has served as the Title Partner of the Nitto ATP Finals―the year-end climax of the men's professional tennis circuit featuring the world’s the top eight s
AIT Worldwide Logistics’ Global Expansion Continues With First Facility in Indonesia17.11.2025 04:01:00 CET | Press release
Jakarta office launches in response to demand for logistics expertise in Southeast Asia As part of its ongoing organic expansion strategy, global supply chain solutions leader, AIT Worldwide Logistics, opened its first office in Jakarta, Indonesia. The new facility represents the eighth country in the AIT-Asia network and exemplifies the company’s adaptability and flexibility in response to customer demands in the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116717860/en/ Teammates gathered to celebrate the grand opening of AIT-Jakarta. According to AIT’s Chief Strategy Officer, Greg Weigel, the team in Jakarta will collaborate with AIT’s expansive global network to quickly customize sea, air and road solutions unique to each client’s organizational needs, with a particular focus on the region’s flourishing industrial, technology and telecommunications sectors. “Jakarta is a pivotal market for us as we continue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom